InterMune (NASDAQ:ITMN), a company whose shares are moving quickly, is trading 2.7% lower to $14.31. The Dow is down 0.7% to 12,573 and the S&P is currently down 0.7% to 1,307.
InterMune has overhead space with shares priced $14.31, or 46.8% below the average consensus analyst price target of $26.92. The stock should run into initial resistance at its 50-day moving average (MA) of $15.65 and subsequent resistance at its 200-day MA of $27.20.
InterMune, Inc. is a biopharmaceutical company. The Company develops therapies for hepatology and pulmonology, including treatments for severe, malignant osteopetrosis and chronic granulomatous disease
Over the past year, InterMune has traded in a range of $10.67 to $51.71 and is now at $14.31, 34% above that low. Over the last five market days, the 200-day moving average (MA) has gone down 2.9% while the 50-day MA has declined 4.4%.
